News

GeneThera has reported a major expansion of its previously reported efforts to commercialize a diagnostic platform for Johne’s disease. The company said that it is preparing to enter

Data published in The Journal of Bone and Joint Surgery demonstrates that use of ChloraPrep is more effective than both DuraPrep and povidone-iodine, at eliminating overall bacteria from

Protalix has received Fast Track Designation from the FDA for prGCD, the company’s proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD). It is intended for the treatment of

Resverlogix has released several quarterly updates for RVX-208, as apotential treatment of atherosclerosis and cardiovascular disease. The company claims that the phase 1b/2a study testing RVX-208 for 28

Myriad Genetics has reported an increase in molecular diagnostic revenue by 47% to $326.5m for fiscal year ended June 30, 2009, compared to $222.9m for the fiscal year

CardioDx, a cardiovascular genomic diagnostics company, has completed its multicenter validation study for Corus CAD. It is a gene expression test to quantify the likelihood of obstructive coronary

Peptimmune has completed phase Ib study of PI-2301. The trial was conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301, in subjects with Secondary Progressive Multiple

Graymark has acquired somniCare and somniTech (collectively, Somni) from Avastra. The Somni companies provide personalized sleep disorder testing and treatment as well as comprehensive care in sleep apnea

BioDelivery Sciences has revealed the issuance of US Patent No. 7,579,019, which will provide additional patent exclusivity for both Onsolis and BDSI’s Bema drug delivery technology platform, until